1. Introduction {#sec1-pharmacy-05-00061}
===============

The QT-interval on an electrocardiogram (EKG) represents the depolarization and repolarization of cardiac ventricles. On a 12-lead EKG, the QT-interval is measured from the beginning of the QRS complex to the end of the T wave as it returns to baseline. Several factors such as gender, heart rate, underlying arrhythmias, and conduction defects influence the QT-interval. The QT-interval will vary depending on heart rate. To standardize the measurement to a heart rate of 60 beats per minute, the QT-interval is corrected and referred to as the QTc \[[@B1-pharmacy-05-00061]\]. The QTc allows for comparison of the QT-interval across a range of heart rates. The most universally adopted method for correcting QT-intervals for heart rate is the Bazett's formula (Corrected QT-interval (QTc): QT/√RR in seconds; RR is the interval from the peak of one QRS complex to the peak of the next as shown on an electrocardiogram) \[[@B1-pharmacy-05-00061]\]. QTc-prolongation is defined as a QTc-interval of \>450 milliseconds (ms) in males, and \>470 ms in females, and can predispose patients to life-threatening ventricular arrhythmias. Several medications have been implicated in the prolongation of the QTc-interval. A complete resource of medications, stratified according to QTc-prolonging risk, can be found at [crediblemeds.com](crediblemeds.com). QTc-prolongation can occur in up to 10% of patients taking QTc-prolonging antiarrhythmics (including amiodarone), and \<1% of patients taking macrolide or fluoroquinolone antibiotics. The concomitant use of two QTc-prolonging medications increases this risk \[[@B1-pharmacy-05-00061]\]. Manufacturers recommend close monitoring for evidence of QTc-prolongation with the concomitant use of QTc-prolonging medications, while previous studies recommend that offending drugs should be discontinued in patients who develop a prolonged QTc-interval \>500 ms, or an increase in QTc-interval of \>60 ms on follow-up EKG \[[@B2-pharmacy-05-00061],[@B3-pharmacy-05-00061],[@B4-pharmacy-05-00061],[@B5-pharmacy-05-00061],[@B6-pharmacy-05-00061],[@B7-pharmacy-05-00061],[@B8-pharmacy-05-00061]\]. However, it is unknown whether EKGs are used to alter prescribing and monitoring habits when these medications are combined. This is the first study to observe the real-life prescribing and monitoring habits for patients taking an antiarrhythmic and a concomitant QTc-prolonging antibiotic at a large, academic medical center.

2. Materials and Methods {#sec2-pharmacy-05-00061}
========================

A retrospective chart review, exempt from IRB-approval, was completed to observe the prescribing and monitoring habits for patients taking an antiarrhythmic and a concomitant QTc-prolonging antibiotic. This study included patients admitted to Einstein Medical Center-Philadelphia from 1 October 2015 to 30 September 2016. Patients were identified with an electronic report of drug interaction alerts that had advised pharmacists during order verification of the increased risk of a QTc-prolonging effect between two medications. Patients taking amiodarone upon admission who also received at least one concomitant dose of ciprofloxacin, moxifloxacin, or azithromycin during admission were included. Gender, QTc-prolonging medication, medication dose, pharmacist interventions, presence or absence of a baseline (while on amiodarone only) and follow-up (while on amiodarone and a QTc-prolonging antibiotic), QTc-interval, change in QTc-interval, and therapy modification and justification were collected. The formula used to calculate the corrected QT-interval was Bazett's formula. Descriptive statistics, including the median and range, were used to analyze patient demographics, prescriptions, and monitoring data.

3. Results {#sec3-pharmacy-05-00061}
==========

A total of 78 patients were assessed, and 42 patients received concomitant QTc-prolonging agents. The most commonly prescribed medication regimen was azithromycin added to home amiodarone therapy in 23 patients (54.5%). Thirty-six out of 42 patients (85.7%) previously taking amiodarone received a baseline EKG ([Table 1](#pharmacy-05-00061-t001){ref-type="table"}). The median male QTc-interval was 473 ms (range: 405--602 ms), and the median female QTc-interval was 470 ms (range: 435--599 ms) ([Table 1](#pharmacy-05-00061-t001){ref-type="table"}). Of the male patients who received a baseline EKG, nine out of 14 (64.2%) had a prolonged QTc-interval (\>450 ms). Of the female patients who received a baseline EKG, 12 out of 22 (54.5%) had a prolonged QTc-interval (\>470 ms) ([Table 1](#pharmacy-05-00061-t001){ref-type="table"}). Of the 36 patients who received a baseline EKG, a pharmacist recommended a follow-up EKG on three occasions (8.3%) ([Table 1](#pharmacy-05-00061-t001){ref-type="table"}). Twenty-three out of 36 patients (63.8%) received a follow-up EKG. The median male QTc-interval was 481 ms (range: 440--628 ms), and the median female QTc-interval was 484 ms (range: 384--645 ms) ([Table 1](#pharmacy-05-00061-t001){ref-type="table"}). Of the male patients who received a follow-up EKG, two out of eight (25%) had a prolonged QTc-interval (\>450 ms). Of the female patients who received a follow-up EKG, 11 out of 15 (73.3%) had a prolonged QTc-interval (\>470 ms) ([Table 1](#pharmacy-05-00061-t001){ref-type="table"}). Ten out of 23 patients (43.5%) had a QTc-interval \>500 ms or an increase in QTc-interval of \>60ms on follow-up EKG, but in only three out of 23 instances (13%), therapy was either discontinued or a different antimicrobial was utilized ([Table 1](#pharmacy-05-00061-t001){ref-type="table"}). Of these three patients, two (66.7%) experienced a QTc-interval increase to \>600 ms without arrhythmia, and one (33.3%) developed torsades de pointes before alternative therapy was utilized. ([Table 1](#pharmacy-05-00061-t001){ref-type="table"}).

4. Discussion {#sec4-pharmacy-05-00061}
=============

Manufacturers recommend close monitoring for evidence of QTc-prolongation with the concomitant use of QTc-prolonging medications, but the monitoring parameters are not well-defined \[[@B2-pharmacy-05-00061],[@B3-pharmacy-05-00061],[@B4-pharmacy-05-00061],[@B5-pharmacy-05-00061]\]. Previous studies have recommended that surveillance EKGs be completed before and after initiation of QTc-prolonging medications \[[@B1-pharmacy-05-00061],[@B6-pharmacy-05-00061],[@B7-pharmacy-05-00061],[@B8-pharmacy-05-00061]\]. This observational study demonstrated that despite prescribers ordering baseline EKGs on most patients, 36.2% of patients still did not receive a follow-up EKG. In the presence of a follow-up EKG, "The Significance of QT-Interval in Drug Development" published in the British Journal of Clinical Pharmacology states that offending drugs should be discontinued in patients who develop an increase of \>60 ms in QTc-interval \[[@B7-pharmacy-05-00061]\]. Additionally, "Practice Standards for Electrocardiographic Monitoring in Hospital Setting" published by the American Heart Association (AHA) states that offending drugs should be discontinued in patients who develop a prolonged QTc-interval \>500 ms \[[@B8-pharmacy-05-00061]\]. In our study, ten patients demonstrated either a QTc-interval \>500 ms, or an increase of \>60 ms in QTC-interval on follow-up EKG. Prescribers infrequently responded with therapy modifications, which may have led to one patient experiencing torsades de pointes. To avoid the potential development of fatal arrhythmias in the setting of a prolonged QTc-interval, alternative antibiotics could be utilized. The Infectious Disease Society of America provides alternative recommendations for specific disease states, and an antibiotic that does not prolong the QTc-interval could be selected. Pharmacists infrequently recommended follow-up monitoring or offered alternative treatment recommendations. Lack of documentation may have led to the perceived small amount of pharmacist interventions. Pharmacists were also not able to view follow-up EKGs, as results are not readily reposted in the electronic medical record. Additional limitations to the study include its small sample size, and other medications or patient-specific characteristics that cause QTc-prolongation were not assessed. Our study showed that the QTc-interval was not optimally monitored in some instances for patients, despite recommendations from manufacturers. For instance, six patients did not receive a baseline EKG, and 13 patients did not receive a follow-up EKG. These results may also be experienced in other institutions, stressing the importance of inter-professional communication to place an emphasis on follow-up monitoring or use of alternative therapy agents to avoid the drug--drug interaction altogether.
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Electrocardiogram (EKG) results and subsequent therapy modifications. QTc: corrected QT-interval.

  ------------------------------------------------------------------------------ ----------------
  Baseline EKG obtained (%)                                                      36/42 (85.7)
  Median male QTc, ms (range)                                                    473 (405--602)
  Male QTc \>450 ms (%)                                                          9/14 (62.4%)
  Median female QTc, ms (range)                                                  470 (435--599)
  Female QTc \>470 ms (%)                                                        12/22 (54.5%)
  Follow-up EKG recommended by pharmacist (%)                                    3/36 (8.3)
  Follow-up EKG obtained (%)                                                     23/36 (63.8)
  Median male QTc, ms (range)                                                    481 (440--628)
  Male QTc \>450 ms (%)                                                          2/8 (25)
  Median female QTc, ms (range)                                                  484 (384--645)
  Female QTc \>470 ms (%)                                                        11/15 (73.3)
  Follow-up EKG QTc-interval \>500 ms, or QTc-interval increase of \>60 ms (%)   10/23 (43.5)
  Therapy changed based on follow-up EKG (%)                                     3/23 (13)
  Patient developed torsades de pointes (%)                                      1/23 (4.3)
  Patient QTc-interval increased to \>600 ms (%)                                 2/23 (8.7)
  ------------------------------------------------------------------------------ ----------------
